EyePoint Pharmaceuticals, Inc. Wields Latest Technology to Advance Ophthalmic Treatments

Photo of author
Written By Joel Gbolade

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts. 

Established in 1987 as pSivida Corp., the company rebranded as EyePoint Pharmaceuticals in 2018 following its acquisition of Icon Bioscience Inc. 

EyePoint specializes in developing ophthalmic treatments for serious eye disorders, leveraging its proprietary Durasert E technology. 

This technology enables the direct delivery of drugs to the eye through in-office intravitreal (IVT) injections, offering sustained release and maximizing drug efficacy while minimizing side effects.

Read More: EyePoint Pharmaceuticals, Inc. Wields Latest Technology to Advance Ophthalmic Treatments

Pinnacle of Modern Health Tech: Durasert E 

EyePoint’s Durasert E technology is a cornerstone of its value proposition. This innovative drug delivery system utilizes a bioerodible matrix to provide continuous release of drugs over an extended period. 

Credits: DepositPhotos

By administering drugs via IVT injection, Durasert E ensures targeted delivery to the eye, eliminating the need for surgical extraction post-treatment.

Importantly, the customizable delivery time allows for personalized treatment plans, ranging from one week to several months.

This technology represents a significant advancement in ophthalmic drug delivery, offering improved efficacy, reduced injection frequency, and personalized treatment options.

EyePoint’s Pipeline Overview 

EyePoint’s pipeline comprises three main programs, each addressing specific ophthalmic needs utilizing the Durasert E technology:

EYP-1901 (Vorolanib): Vorolanib, a tyrosine kinase inhibitor, targets abnormal blood vessel growth and leakage observed in wet Age-related Macular Degeneration (wet AMD), Non-Proliferative Diabetic Retinopathy (NPDR), and Diabetic Macular Edema (DME). 

Phase 2 clinical trials for wet AMD have demonstrated positive topline results, with Phase 3 trials expected in the second half of 2024. Additionally, Phase 2 trials for NPDR are underway, with data anticipated in Q2 2024, while Phase 2 trials for DME are ongoing, with results expected in Q1 2025.

EYP-2301 (Razuprotafib): Razuprotafib targets the treatment of glaucoma and ocular hypertension. Phase 3 clinical trials are currently underway, with topline results expected in the second half of 2024.

Complement Inhibition: EyePoint is also exploring complement inhibition for the treatment of retinal vein occlusion (RVO). Phase 1 clinical trials have shown promising results, with further development expected in the future.

Also Read: Major U.S. Banks Grapple With Rising Bad Property Debt and Depleted Reserves

EYP-1901 Emerges as a Contender in Wet AMD Treatment

EyePoint Pharmaceuticals (NASDAQ: EYPT) recently unveiled positive Phase 2 clinical trial results for EYP-1901 (Vorolanib) in treating wet Age-related Macular Degeneration (AMD). 

Administered using the innovative Durasert E drug delivery technology, EYP-1901 demonstrated efficacy comparable to Regeneron’s aflibercept (Eylea), the current standard treatment.

The trial indicated that EYP-1901 could offer cost and dosing advantages over Eylea, potentially becoming a compelling option for wet AMD patients. 

The market responded favorably to this development, with EYPT shares surging approximately 261%.

Furthermore, EYP-1901 exhibited no significant adverse effects during the trial. The positive outcome paves the way for smaller Phase 3 trials to validate the drug’s effectiveness against aflibercept.

Moreover, upcoming Phase 2 results for another indication, Non-Proliferative Diabetic Retinopathy (NPDR), expected in Q2 2024, could serve as a catalyst for further share price movement.

EYP-2301: Exploring Razuprotafib

EyePoint’s EYP-2301 program focuses on razuprotafib, a TIE-2 agonist designed to regulate blood vessel stability and inhibit the formation of new blood vessels in serious retinal diseases. 

While promising, razuprotafib remains in the preclinical trial phase, with toxicology and pharmacokinetics data expected in 2024. 

While this program holds potential, it is not currently considered a primary value driver for EyePoint.

Targeting Geographic Atrophy

EyePoint’s Complement Inhibition research program aims to address Geographic Atrophy (GA), an advanced form of AMD, by enhancing the ability of antibodies to clear microbes and damaged cells.

Successful research in this area could potentially prevent vision loss for some patients. However, the program is still in the discovery phase, with the possibility of a product candidate emerging in 2024.

Valuation Analysis

Despite its promising pipeline, EyePoint’s valuation appears stretched.

Credits: DepositPhotos

With projected revenues of $44.1 million for 2024, the company’s implied price-to-sales (P/S) multiple stands at approximately 30.2, significantly higher than the sector’s median of 4.0. 

Additionally, EyePoint holds approximately $136.0 million in cash and $6.2 million in total debt. 

However, with a quarterly cash burn of $16.9 million, the company’s cash runway of approximately 2.0 years raises concerns, especially in the absence of significant cash inflows in the near term.

A “Hold” Recommendation

While EyePoint shows promise in advancing eye care research, its stretched valuation and cash runway considerations warrant a cautious approach. 

Despite optimism surrounding its pipeline, a “buy” rating may not be justified at present.

Instead, a “hold” recommendation seems prudent until further clarity emerges regarding the company’s financial performance and research developments.

Read Next: Will This Company’s Strategic Approach be Enough to Transcend Global Volatility in the Oil Industry?


You should read and understand this disclaimer in its entirety before joining or viewing the website or email/blog list of SmallCapStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: www.SmallCapStocks.com/Disclaimer and www.SmallCapStocks.com/Privacy-Policy

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.